Navigation Links
Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Date:11/9/2007

erious infections and allergic reactions. Also, rare cases of certain kinds of cancers have been reported.

People taking ORENCIA are at increased risk for developing infections including pneumonia, and other infections caused by viruses, bacteria, or fungi. Individuals should call their doctor immediately if they feel sick or get any infection during treatment with ORENCIA.

Allergic reactions are usually mild or moderate, generally occur within the first 24 hours of an infusion, and include hives, swollen face, eyelids, lips, tongue, throat, or trouble breathing. There have been some serious allergic reactions reported in people that received an infusion of ORENCIA.

There have been rare cases of certain kinds of cancer in people receiving ORENCIA. The role of ORENCIA in the development of cancer is not known. The more common side effects with ORENCIA are headache, upper respiratory tract infection, sore throat, and nausea.

For Full Prescribing Information, please visit http://www.ORENCIA.com or http://www.bms.com

Bristol-Myers Squibb Company is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

* Based on the percentages of patients achieving ACR 20, 50 and 70 responses, indicating 20 percent, 50 percent and 70 percent improvements in ACR criteria, respectively.


'/>"/>
SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
5. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
6. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
9. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
11. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 2015 A global continuing medical ... and thyroid disorders in Central and South-East ... a major conference dedicated to these diseases. ... Online , Manage Hypertension Online and ... by EXCEMED - combine the world,s top ...
(Date:7/3/2015)... July 3, 2015 Un ... épidémies que sont l,hypertension, le diabète et les ... plateformes éducatives gratuites et d,une conférence majeure dédiée ... http://photos.prnewswire.com/prnh/20150630/227033 ) , Les formations ... , Prendre en charge l,hypertension en ligne ...
(Date:7/3/2015)... 3, 2015 Der ... bestimmter Abschlussbedingungen eine 100-prozentige Beteiligung am Unternehmen ... Mit dieser Übernahme dringt Lupin in den ... von 765 Mrd. RUB im Jahr 2014 ... gehörte (IMS Health). Seit über einem Jahrzehnt ...
Breaking Medicine Technology:Combating Three Major Chronic Diseases in Central and South-East Asia With Medical Education 2Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 3Lupin übernimmt Biocom aus Russland 2Lupin übernimmt Biocom aus Russland 3
... PITTSBURGH, Oct. 13 BIOSAFE, Inc. , a ... has announced that they are launching in specific markets ... with BIOSAFE (®) . Crosstex, new BIOSAFE-treated Ultra ... VRE, and Staph immediately upon contact, and have further ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced ... 3,000,000 shares of its common stock at a price ... from the sale of shares in this offering, after ... expenses, were approximately $20.9 million. Sangamo intends to use ...
Cached Medicine Technology:BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 2BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 3BIOSAFE Launching In a New Specially-Treated Facemask Effective Against H1N1 Influenza 4Sangamo Announces Closing of Common Stock Offering 2Sangamo Announces Closing of Common Stock Offering 3
(Date:7/5/2015)... MN (PRWEB) , ... July 06, 2015 , ... ... the ancillary benefits market, is excited to announce the next generation of PrimeStar ... and Advantage plans to now include two network options—Maximum Allowable Charge (MAC) and ...
(Date:7/5/2015)... Raleigh, NC (PRWEB) , ... July 05, 2015 , ... ... good data-gathering, a new IMRT/surgery combination may one day change the outlook for people ... to read it now. , Researchers report that five mesothelioma patients treated ...
(Date:7/4/2015)... , ... July 04, 2015 , ... ... solar industry’s leading recognition of technical sales expertise from the North American Board ... Sales ProfessionalTM. NABCEP is the most highly respected and well established national certification ...
(Date:7/3/2015)... ... July 03, 2015 , ... Scientists at several top US cancer centers believe ... asbestos exposure. Click here to read the complete story , just posted on ... Cedars Sinai Medical Center, and New York University exposed mice with a mutation on ...
(Date:7/3/2015)... , ... July 03, 2015 , ... Smoothies are all ... a good blender and easily accessible, quality ingredients. Aurora Natural is proud to introduce ... an added boost of fiber, protein, antioxidants, vitamins and minerals! , Aurora is offering ...
Breaking Medicine News(10 mins):Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2
... /PRNewswire-FirstCall/ - MDS Nordion, a leading,provider of ... to their medical isotope customers about a ... from their primary supplier regarding,an interruption in ... manufacturing of,technetium-99m generators and iodine-131. The primary ...
... States,Golf Association (USGA) awarded a $20,000 matching grant to ... Program and the creation of a golf program at ... the USGA has supported programs that bring the game,of ... PGA Golf Pro,who leads the Winter Therapeutic Golf Clinics ...
... Nov. 30 Journalists from leading U.S.,news organizations ... organized by the,United Nations and the National Association ... on the impact of climate change, the fight ... the framework of the Millennium Development Goals (MDGs)., ...
... MD (November 30, 2007) Concerns over possible radiation effects ... New England Journal of Medicine should not scare people away ... a critical role in saving the lives of thousands of ... Association of Physicists in Medicine (AAPM). , In a statement ...
... a third, study found , , FRIDAY, Nov. 30 (HealthDay ... significantly slows the decline in lung function seen in ... team at Case Western Reserve University School of Medicine, ... took high doses of ibuprofen twice a day had ...
... Caraco Pharmaceutical,Laboratories, Ltd., (Amex: CPD ) announced ... has granted tentative approval for the Company,s,Abbreviated New ... mg, 10 mg, and 20 mg., Escitalopram ... This tentative approval is for the generic bioequivalent ...
Cached Medicine News:Health News:MDS Nordion Provides Update to Medical Isotope Customers 2Health News:Marianjoy Rehabilitation Hospital Therapeutic Golf Program Receives a $20,000 Matching Grant From the USGA 2Health News:NABJ Joins with U.N. to Cover Climate Change and Development in Senegal 2Health News:NABJ Joins with U.N. to Cover Climate Change and Development in Senegal 3Health News:Hazards of CT scans overstated 2Health News:Ibuprofen Preserves Lung Function in Kids With Cystic Fibrosis 2Health News:Ibuprofen Preserves Lung Function in Kids With Cystic Fibrosis 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R) 2
Features four-way apron closure for super adjustability to fit staff of all shapes and sizes. Top left and right shoulder closures allow adjustment of armhole size and chest area of apron for close a...
Freedom of movement - plus full circle, maximum radiation protection. No other full circle radiation protection design approaches the level of comfort of the VestSkirt, which divides weight between t...
Use this workhorse apron where 360 of protection from direct and scatter radiation is required....
Bio-Rad's Genetic Systems™ HBsAg EIA 3.0 screening and confirmatory assays offer outstanding sensitivity and early detection of HBV infection, helping to meet your testing criteria....
Medicine Products: